Daniel Kofink1, Ruben N Eppinga1, Wiek H van Gilst1, Stephan J L Bakker1, Robin P F Dullaart1, Pim van der Harst1, Folkert W Asselbergs2. 1. From the Department of Cardiology, Division of Heart and Lungs, University Medical Center Utrecht, University of Utrecht, The Netherlands (D.K., F.W.A.); Department of Cardiology (R.N.E., W.H.v.G., P.v.d.H.), Department of Internal Medicine (S.J.L.B.), and Department of Endocrinology, University Medical Center Groningen (R.P.F.D.), University of Groningen, The Netherlands; Durrer Center for Cardiogenetic Research, ICIN-Netherlands Heart Institute, Utrecht (P.v.d.H., F.W.A.); and Institute of Cardiovascular Science, Faculty of Population Health Sciences, University College London, United Kingdom (F.W.A.). 2. From the Department of Cardiology, Division of Heart and Lungs, University Medical Center Utrecht, University of Utrecht, The Netherlands (D.K., F.W.A.); Department of Cardiology (R.N.E., W.H.v.G., P.v.d.H.), Department of Internal Medicine (S.J.L.B.), and Department of Endocrinology, University Medical Center Groningen (R.P.F.D.), University of Groningen, The Netherlands; Durrer Center for Cardiogenetic Research, ICIN-Netherlands Heart Institute, Utrecht (P.v.d.H., F.W.A.); and Institute of Cardiovascular Science, Faculty of Population Health Sciences, University College London, United Kingdom (F.W.A.). f.w.asselbergs@umcutrecht.nl p.van.der.harst@umcg.nl.
Abstract
BACKGROUND: Statins lower cholesterol by inhibiting HMG-CoA reductase, the rate-limiting enzyme of the metabolic pathway that produces cholesterol and other isoprenoids. Little is known about their effects on metabolite and lipoprotein subclass profiles. We, therefore, investigated the molecular changes associated with pravastatin treatment compared with placebo administration using a nuclear magnetic resonance-based metabolomics platform. METHODS AND RESULTS: We performed metabolic profiling of 231 lipoprotein and metabolite measures in the PREVEND IT (Prevention of Renal and Vascular End-stage Disease Intervention Trial) study, a placebo-controlled randomized clinical trial designed to test the effects of pravastatin (40 mg once daily) on cardiovascular risk. Metabolic profiles were assessed at baseline and after 3 months of treatment. Pravastatin lowered low-density lipoprotein cholesterol (change in SD units [95% confidence interval]: -1.01 [-1.14, -0.88]), remnant cholesterol (change in SD units [95% confidence interval]: -1.03 [-1.17, -0.89]), and apolipoprotein B (change in SD units [95% confidence interval]: -0.98 [-1.11, -0.86]) with similar effect magnitudes. In addition, pravastatin globally lowered levels of lipoprotein subclasses, with the exception of high-density lipoprotein subclasses, which displayed a more heterogeneous response pattern. The lipid-lowering effect of pravastatin was accompanied by selective changes in lipid composition, particularly in the cholesterol content of very-low-density lipoproteinparticles. In addition, pravastatin reduced levels of several fatty acids but had limited effects on fatty acid ratios. CONCLUSIONS: These randomized clinical trial data demonstrate the widespread effects of pravastatin treatment on lipoprotein subclass profiles and fatty acids. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT03073018.
RCT Entities:
BACKGROUND: Statins lower cholesterol by inhibiting HMG-CoA reductase, the rate-limiting enzyme of the metabolic pathway that produces cholesterol and other isoprenoids. Little is known about their effects on metabolite and lipoprotein subclass profiles. We, therefore, investigated the molecular changes associated with pravastatin treatment compared with placebo administration using a nuclear magnetic resonance-based metabolomics platform. METHODS AND RESULTS: We performed metabolic profiling of 231 lipoprotein and metabolite measures in the PREVEND IT (Prevention of Renal and Vascular End-stage Disease Intervention Trial) study, a placebo-controlled randomized clinical trial designed to test the effects of pravastatin (40 mg once daily) on cardiovascular risk. Metabolic profiles were assessed at baseline and after 3 months of treatment. Pravastatin lowered low-density lipoprotein cholesterol (change in SD units [95% confidence interval]: -1.01 [-1.14, -0.88]), remnant cholesterol (change in SD units [95% confidence interval]: -1.03 [-1.17, -0.89]), and apolipoprotein B (change in SD units [95% confidence interval]: -0.98 [-1.11, -0.86]) with similar effect magnitudes. In addition, pravastatin globally lowered levels of lipoprotein subclasses, with the exception of high-density lipoprotein subclasses, which displayed a more heterogeneous response pattern. The lipid-lowering effect of pravastatin was accompanied by selective changes in lipid composition, particularly in the cholesterol content of very-low-density lipoproteinparticles. In addition, pravastatin reduced levels of several fatty acids but had limited effects on fatty acid ratios. CONCLUSIONS: These randomized clinical trial data demonstrate the widespread effects of pravastatin treatment on lipoprotein subclass profiles and fatty acids. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT03073018.
Authors: Lukas Andereggen; Janine Frey; Robert H Andres; Markus M Luedi; Jan Gralla; Gerrit A Schubert; Jürgen Beck; Luigi Mariani; Emanuel Christ Journal: J Clin Transl Endocrinol Date: 2021-06-17
Authors: Kirsty E Waddington; George A Robinson; Leda Coelewij; Elvira Chocano; Thomas McDonnell; Filipa Farinha; Junjie Peng; Pierre Dönnes; Edward Smith; Sara Croca; Jyoti Bakshi; Maura Griffin; Andrew Nicolaides; Anisur Rahman; Elizabeth C Jury; Ines Pineda-Torra Journal: Arterioscler Thromb Vasc Biol Date: 2021-02-04 Impact factor: 10.514
Authors: Naveed Sattar; Adam Butterworth; Peter Würtz; Eeva Sliz; Johannes Kettunen; Michael Holmes; Clare Williams; Charles Boachie; Qin Wang; Minna Männikkö; Sylvain Sebert; Robin Walters; Kuang Lin; Lona Millwood; Robert Clarke; Liming Li; N Rankin; Paul Welsh; Christian Delles; J Jukema; Stella Trompet; Ian Ford; Markus Perola; Veikko Salomaa; Marjo-Riitta Järvelin; Zhengming Chen; Debbie Lawlor; Mika Ala-Korpela; John Danesh; George Smith Journal: Circulation Date: 2018-11-27 Impact factor: 29.690
Authors: Michael G Levin; Verena Zuber; Venexia M Walker; Derek Klarin; Julie Lynch; Rainer Malik; Aaron W Aday; Leonardo Bottolo; Aruna D Pradhan; Martin Dichgans; Kyong-Mi Chang; Daniel J Rader; Philip S Tsao; Benjamin F Voight; Dipender Gill; Stephen Burgess; Scott M Damrauer Journal: Circulation Date: 2021-06-18 Impact factor: 29.690
Authors: Ben Henderson; Guilherme Lopes Batista; Carlo G Bertinetto; Joris Meurs; Dušan Materić; Coen C W G Bongers; Neeltje A E Allard; Thijs M H Eijsvogels; Rupert Holzinger; Frans J M Harren; Jeroen J Jansen; Maria T E Hopman; Simona M Cristescu Journal: Metabolites Date: 2021-03-24